| Patent application number | Description | Published |
|---|
| 20100098707 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 04-22-2010 |
| 20100297132 | Monoclonal antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 11-25-2010 |
| 20110070613 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 03-24-2011 |
| Patent application number | Description | Published |
|---|
| 20090156529 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 06-18-2009 |
| 20100190714 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 07-29-2010 |
| 20100210513 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-19-2010 |
| 20100210514 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-19-2010 |
| 20100216971 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-26-2010 |
| 20100216972 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-26-2010 |
| Patent application number | Description | Published |
|---|
| 20090099072 | Motif of the Beclin Protein Which Interacts with Anti-Apoptotic Members of the Bcl-2 Protein Family, and Uses - The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarisation. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death. The invention also relates to a motif of the Beclin protein which can interact with an anti-apoptic member of the family of Bcl-2 proteins and to the use thereof in order to induce programmed cell death in a cancer patient. | 04-16-2009 |
| 20090325883 | Peptides Which Interact with Anti-Apoptotic Members of the BCL-2 Protein Family, and Uses - The invention lies within the field of seeking out and identifying new peptides which interact with anti-apoptotic members of the Bcl-2 protein family, by means of the two-hybrid system. | 12-31-2009 |
| 20100168149 | Camptothecin Analogue Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compound of formula (I): | 07-01-2010 |
| 20100168150 | Camptothecin Analogue Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them. - Compound of formula (I): | 07-01-2010 |
| 20110034460 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 02-10-2011 |
| 20110112104 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. - Compounds of formula (I): | 05-12-2011 |
| 20110237644 | UBIQUITIN SPECIFIC PROTEASES RESPONSIBLE FOR MCL-1 STABILITY AND USES THEREOF - Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer. | 09-29-2011 |
